A multicenter randomized double-masked clinical trial of a new formulation of topical Cysteamine for the treatment of Corneal Cystine Crystals in cystinosis
Prograf as secondary intervention vs continuation of cyclosporine in patients at risk for chronic renal allograft failure (CRAF) results in improved renal function, decreased CV risk, and no increased risk for diabetes